Skip to content

Pharmacokinetics of oral Δ9-tetrahydrocannabinol (THC) administration in vervet monkeys

F. Huppé-Gourgues, Natalie Spridzans, S. Lamarre, A. Beierschmitt, R. Palmour, Jean-François Bouchard, Maurice Ptito

Journal of Cannabis Research March 24, 2026 DOI: 10.1186/s42238-026-00422-y (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational pharmacokinetic study Peer reviewed
Population Vervet monkeys
Interventions THC CBD
Duration Acute and short chronic exposure (day 1 and day 8)
Measures HPLC-MS/MS
Topics Cannabis
Key findings After oral THC administration in vervet monkeys, THC and 11-OH-THC concentrations rose and peaked around 4 hours post-ingestion on both day 1 and day 8 across dose groups. Baseline THC on day 8 was higher than on day 1. CBD increased only on day 1 at the highest dose, and THC-COOH did not increase significantly.

Abstract

Cannabis and its primary psychoactive component, Δ9-tetrahydrocannabinol (THC), are increasingly studied for their pharmacological effects, yet little is known about their pharmacokinetics in non-human primates. This study aimed to characterize the pharmacokinetic profile of THC and its metabolites following oral administration in vervet monkeys under both acute and short chronic exposure conditions. Using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), we quantified delta 9-THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THC-COOH) in blood samples. THC concentrations increased after dosing, with peak values observed around 4 h post-ingestion. On day 1 and day 8, the 4-hour increase was observed across dose groups. The baseline (0 h) THC on Day 8 was increased when compared to Day 1. 11-OH-THC showed a similar peak around 4 h time course. CBD was increased only at day 1 for the highest dose and THC-COOH was not significantly increased. These findings provide a pharmacokinetic foundation for future research on THC’s therapeutic and behavioral effects in vervet monkeys and help inform dosing strategies for translational studies. Supplementary Information The online version contains supplementary material available at 10.1186/s42238-026-00422-y.

Comparable studies

Other preclinical and animal studies on cannabis, most cited first.

Study Year Design Participants
Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors Mice 2015 Preclinical study
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). hMDR1- and hBCRP-transfected HEK293 cells and hMDR1- and hBCRP-MDCKII cells 2010 In vitro study
Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure Mice prenatally exposed to THC, including conditional CB1R knockout mice 2020 Animal experimental study
Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway Mice exposed to chronic THC early in life 2018 Animal experimental study
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Spontaneously hypertensive rats (SHRs) and Wistar rats 2014 Animal experimental study

Explore topics